WST - West Pharmaceutical Services, Inc.
NYSE
->
Healthcare
->
Medical Instruments & Supplies
Exton,
United States
Type: Equity
WST price evolution
WST
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $853.9 | $898.6 | $796.3 | $886.3 |
| Short term investments | ||||
| Net receivables | $512 | $519.1 | $534.4 | $513.4 |
| Inventory | $434.7 | $431.8 | $449.4 | $447 |
| Total current assets | $1936.4 | $1972.3 | $1874.2 | $1937.2 |
| Long term investments | $210 | $195.4 | $202.8 | $208.8 |
| Property, plant & equipment | $1512.5 | $1408.4 | $1360.5 | $1316.3 |
| Goodwill & intangible assets | $123.6 | $122.5 | $124.8 | $125.6 |
| Total noncurrent assets | $1893.1 | $1782.4 | $1795.4 | $1786.4 |
| Total investments | $210 | $195.4 | $202.8 | $208.8 |
| Total assets | $3829.5 | $3754.7 | $3669.6 | $3723.6 |
| Current liabilities | ||||
| Accounts payable | $242.4 | $219.8 | $218 | $233.8 |
| Deferred revenue | ||||
| Short long term debt | $151.7 | $71.7 | $18.4 | $18.4 |
| Total current liabilities | $671.8 | $533.5 | $511.6 | $534.9 |
| Long term debt | $157.3 | $235.1 | $292.9 | $296 |
| Total noncurrent liabilities | $276.7 | $353 | $411.3 | $412.5 |
| Total debt | $309 | $306.8 | $311.3 | $314.4 |
| Total liabilities | $948.5 | $886.5 | $922.9 | $947.4 |
| Shareholders' equity | ||||
| Retained earnings | $3523.4 | $3415.9 | $3254.6 | $3113.6 |
| Other shareholder equity | -$143.8 | -$223 | -$183.5 | -$168.4 |
| Total shareholder equity | $2881 | $2868.2 | $2746.7 | $2776.2 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $853.9 | $894.3 | $762.6 | $615.5 |
| Short term investments | ||||
| Net receivables | $512 | $507.4 | $489 | $385.3 |
| Inventory | $434.7 | $414.8 | $378.4 | $321.3 |
| Total current assets | $1936.4 | $1919.5 | $1742 | $1373.7 |
| Long term investments | $210 | $204.9 | $207.7 | $214.7 |
| Property, plant & equipment | $1512.5 | $1262.7 | $1126.8 | $1011.5 |
| Goodwill & intangible assets | $123.6 | $125.7 | $132.9 | $141.6 |
| Total noncurrent assets | $1893.1 | $1697.3 | $1571.8 | $1420.1 |
| Total investments | $210 | $204.9 | $207.7 | $214.7 |
| Total assets | $3829.5 | $3616.8 | $3313.8 | $2793.8 |
| Current liabilities | ||||
| Accounts payable | $242.4 | $215.4 | $232.2 | $213.1 |
| Deferred revenue | ||||
| Short long term debt | $151.7 | $18.2 | $53.5 | $12.4 |
| Total current liabilities | $671.8 | $519 | $594.1 | $503.4 |
| Long term debt | $157.3 | $206.7 | $271.8 | $313.3 |
| Total noncurrent liabilities | $276.7 | $412.9 | $384.3 | $435.9 |
| Total debt | $309 | $317.9 | $325.3 | $325.7 |
| Total liabilities | $948.5 | $931.9 | $978.4 | $939.3 |
| Shareholders' equity | ||||
| Retained earnings | $3523.4 | $2987.8 | $2456.7 | $1846.7 |
| Other shareholder equity | -$143.8 | -$184.6 | -$159.6 | -$110.6 |
| Total shareholder equity | $2881 | $2684.9 | $2335.4 | $1854.5 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $732 | $747.4 | $753.8 | $716.6 |
| Cost of revenue | $453.8 | $459.1 | $462.4 | $445.3 |
| Gross Profit | $278.2 | $288.3 | $291.4 | $271.3 |
| Operating activities | ||||
| Research & development | $18.4 | $16.4 | $16.5 | $17.1 |
| Selling, general & administrative | $90 | $89 | $88.4 | $86 |
| Total operating expenses | $117.3 | $111 | $108.9 | $116 |
| Operating income | $160.9 | $177.3 | $182.5 | $155.3 |
| Income from continuing operations | ||||
| EBIT | $172.7 | $193.6 | $192.6 | $165.8 |
| Income tax expense | $34.5 | $29.4 | $34.8 | $23.6 |
| Interest expense | $1.2 | $2.9 | $2.7 | $2.2 |
| Net income | ||||
| Net income | $137 | $161.3 | $155.1 | $140 |
| Income (for common shares) | $137 | $161.3 | $155.1 | $140 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2949.8 | $2886.9 | $2831.6 | $2146.9 |
| Cost of revenue | $1820.6 | $1750.7 | $1655.8 | $1379.1 |
| Gross Profit | $1129.2 | $1136.2 | $1175.8 | $767.8 |
| Operating activities | ||||
| Research & development | $68.4 | $58.5 | $52.8 | $46.9 |
| Selling, general & administrative | $353.4 | $316.9 | $362.8 | $302 |
| Total operating expenses | $453.2 | $402.2 | $423.5 | $360.9 |
| Operating income | $676 | $734 | $752.3 | $406.9 |
| Income from continuing operations | ||||
| EBIT | $724.7 | $708.5 | $777.2 | $426.9 |
| Income tax expense | $122.3 | $114.7 | $107.2 | $72.5 |
| Interest expense | $9 | $7.9 | $8.2 | $8.2 |
| Net income | ||||
| Net income | $593.4 | $585.9 | $661.8 | $346.2 |
| Income (for common shares) | $593.4 | $585.9 | $661.8 | $346.2 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $137 | $161.3 | $155.1 | $140 |
| Operating activities | ||||
| Depreciation | $35.9 | $35.7 | $34.1 | $31.6 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.4 | $5.9 | $7.5 | $8.5 |
| Total cash flows from operations | $239.1 | $230.1 | $169.2 | $138.1 |
| Investing activities | ||||
| Capital expenditures | -$108.7 | -$95.8 | -$75.4 | -$82.1 |
| Investments | ||||
| Total cash flows from investing | -$108.8 | -$95.7 | -$82.1 | -$82.1 |
| Financing activities | ||||
| Dividends paid | -$14.8 | -$14 | -$14.1 | -$14.1 |
| Sale and purchase of stock | -$175.8 | -$9.5 | -$163.9 | -$58.1 |
| Net borrowings | -$0.6 | -$0.6 | -$0.5 | -$0.6 |
| Total cash flows from financing | -$189.5 | -$22.3 | -$176.8 | -$71 |
| Effect of exchange rate | $14.5 | -$9.8 | -$0.3 | $7 |
| Change in cash and equivalents | -$44.7 | $102.3 | -$90 | -$8 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $593.4 | $585.9 | $661.8 | $346.2 |
| Operating activities | ||||
| Depreciation | $137.3 | $120.6 | $122.3 | $109.1 |
| Business acquisitions & disposals | -$2.2 | |||
| Stock-based compensation | $23.3 | $23.7 | $37.5 | $34 |
| Total cash flows from operations | $776.5 | $724 | $584 | $472.5 |
| Investing activities | ||||
| Capital expenditures | -$362 | -$284.6 | -$253.4 | -$174.4 |
| Investments | ||||
| Total cash flows from investing | -$368.7 | -$288.2 | -$253.1 | -$179.5 |
| Financing activities | ||||
| Dividends paid | -$57 | -$54.1 | -$51.1 | -$48.1 |
| Sale and purchase of stock | -$407.3 | -$201.3 | -$122.5 | -$93.1 |
| Net borrowings | -$2.3 | -$45.5 | -$2.2 | -$2.3 |
| Total cash flows from financing | -$459.6 | -$293.6 | -$168.1 | -$137.1 |
| Effect of exchange rate | $11.4 | -$10.5 | -$15.7 | $20.5 |
| Change in cash and equivalents | -$40.4 | $131.7 | $147.1 | $176.4 |
News
Fundamentals
| Market cap | $27.74B |
|---|---|
| Enterprise value | $27.19B |
| Shares outstanding | 73.50M |
| Revenue | $2.95B |
|---|---|
| EBITDA | $862.00M |
| EBIT | $724.70M |
| Net Income | $593.40M |
| Revenue Q/Q | 3.29% |
| Revenue Y/Y | 2.18% |
| P/E ratio | 46.74 |
|---|---|
| EV/Sales | 9.22 |
| EV/EBITDA | 31.54 |
| EV/EBIT | 37.52 |
| P/S ratio | 9.40 |
| P/B ratio | 9.17 |
| Book/Share | 41.15 |
| Cash/Share | 11.62 |
| EPS | $8.07 |
|---|---|
| ROA | 15.85% |
| ROE | 21.06% |
| Debt/Equity | 0.33 |
|---|---|
| Net debt/EBITDA | 0.11 |
| Current ratio | 2.88 |
| Quick ratio | 2.24 |